Alvotech Stock Performance
| ALVO Stock | USD 13.27 0.04 0.30% |
Alvotech has a performance score of 6 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Alvotech are expected to decrease at a much lower rate. During the bear market, Alvotech is likely to outperform the market. Alvotech right now shows a risk of 1.65%. Please confirm Alvotech value at risk, as well as the relationship between the skewness and day median price , to decide if Alvotech will be following its price patterns.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Alvotech are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Alvotech may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Actual Historical Performance (%)
One Day Return 0.15 | Five Day Return (2.29) | Year To Date Return 0.68 | Ten Year Return 18.41 | All Time Return 18.41 |
1 | Alvotech veitt auki markasleyfi Bandarkjunum fyrir Selarsdi , lftknilyfjahlistu vi Stelara, til meferar sjkdma meltingarvegi | 10/22/2024 |
2 | Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 1920, 2024 | 10/25/2024 |
3 | European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi | 11/04/2024 |
4 | Alvotech Trading Down 3.55 percent on Nov 11 | 11/11/2024 |
5 | Alvotech Q3 2024 Earnings Call Highlights Record Revenue Growth and Strategic Advancements | 11/15/2024 |
6 | Alvotech Shares Gap Down to 11.94 on Nov 22 | 11/22/2024 |
7 | Is Alvotech Stock Outpacing Its Medical Peers This Year | 12/12/2024 |
8 | Alvotech Joins Nasdaq Biotechnology Index A Strategic Milestone | 12/23/2024 |
9 | Are Medical Stocks Lagging Alvotech This Year | 12/30/2024 |
10 | Has Alvotech Outpaced Other Medical Stocks This Year | 01/15/2025 |
| Begin Period Cash Flow | 66.4 M |
Alvotech |
Alvotech Relative Risk vs. Return Landscape
If you would invest 1,225 in Alvotech on October 20, 2024 and sell it today you would earn a total of 102.00 from holding Alvotech or generate 8.33% return on investment over 90 days. Alvotech is currently generating 0.1445% in daily expected returns and assumes 1.6483% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Alvotech, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alvotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alvotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alvotech, and traders can use it to determine the average amount a Alvotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0877
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ALVO | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.65 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Alvotech is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alvotech by adding it to a well-diversified portfolio.
Alvotech Fundamentals Growth
Alvotech Stock prices reflect investors' perceptions of the future prospects and financial health of Alvotech, and Alvotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alvotech Stock performance.
| Return On Asset | -0.0761 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | 0.46 % | ||||
| Current Valuation | 5.06 B | ||||
| Shares Outstanding | 301.94 M | ||||
| Price To Sales | 12.94 X | ||||
| Revenue | 91.43 M | ||||
| Gross Profit | 150.62 M | ||||
| EBITDA | (484.86 M) | ||||
| Net Income | (551.73 M) | ||||
| Cash And Equivalents | 128.44 M | ||||
| Cash Per Share | 0.52 X | ||||
| Total Debt | 1.08 B | ||||
| Current Ratio | 0.86 X | ||||
| Book Value Per Share | (3.50) X | ||||
| Cash Flow From Operations | (312.19 M) | ||||
| Earnings Per Share | (1.85) X | ||||
| Market Capitalization | 3.99 B | ||||
| Total Asset | 950.09 M | ||||
| Retained Earnings | (2.21 B) | ||||
| Working Capital | (66.11 M) | ||||
About Alvotech Performance
By examining Alvotech's fundamental ratios, stakeholders can obtain critical insights into Alvotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alvotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 194.23 | 316.75 | |
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | 0.53 | 0.49 |
Things to note about Alvotech performance evaluation
Checking the ongoing alerts about Alvotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alvotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alvotech has high likelihood to experience some financial distress in the next 2 years | |
| Alvotech currently holds 1.08 B in liabilities. Alvotech has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Alvotech's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 91.43 M. Net Loss for the year was (551.73 M) with profit before overhead, payroll, taxes, and interest of 150.62 M. | |
| Alvotech currently holds about 128.44 M in cash with (312.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52. | |
| Roughly 64.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Has Alvotech Outpaced Other Medical Stocks This Year |
- Analyzing Alvotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alvotech's stock is overvalued or undervalued compared to its peers.
- Examining Alvotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alvotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alvotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alvotech's stock. These opinions can provide insight into Alvotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.85) | Revenue Per Share | Quarterly Revenue Growth 43.997 | Return On Assets |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.